Key Takeaways
- • Lumira Ventures and Terry Fox Foundation announced an oversubscribed first close of the Cancer Breakthrough Fund, exceeding the original $30 million target with commitments now positioned to reach a hard cap of $50 million at final close.
- • The Canadian Cancer Society has joined as a foundational partner and is investing up to $10 million, integrating charitable scientific networks with venture capital expertise to fund innovative cancer-focused companies.
- • The fund's investor base includes impact-driven foundations and family offices such as Rally Assets (Realize Fund I), Boann Social Impact, and Northpine Foundation, representing newly committed capital to Canada's life sciences sector.
- • The Cancer Breakthrough Fund has already approved its first investment in a Canadian company and maintains a robust pipeline of cancer-focused opportunities designed to deliver both economic returns and patient impact.
- • This represents a first-of-its-kind mission-driven venture capital structure in Canada, blending investment expertise with the scientific networks of two of Canada's leading cancer charities.
Summary
Lumira Ventures and the Terry Fox Foundation announced the successful first close of the Cancer Breakthrough Fund, a mission-driven venture capital fund designed to accelerate funding for innovative cancer companies in Canada. The fund's first close was oversubscribed, with initial commitments exceeding the original $30 million target. The founding partners are now targeting a hard cap of $50 million at final close, reflecting strong investor demand for this investment vehicle.
The Canadian Cancer Society joined as a foundational partner in the initiative, committing up to $10 million in capital. This partnership creates a unique structure combining venture capital investment expertise with the established scientific networks of two of Canada's largest cancer charities. The fund's investor base includes impact- and mission-driven foundations and family offices, notably Rally Assets (Realize Fund I), Boann Social Impact, and Northpine Foundation. All capital committed to date represents new funding directed toward Canada's life sciences innovation sector.
The fund has already approved its first investment in a Canadian company and is advancing a pipeline of cancer-focused opportunities. The stated dual objective is to translate Canadian scientific advances into transformative products for patients while generating strong economic returns for investors. This structure reflects a broader trend of integrating philanthropic missions with venture capital returns, positioning the fund to address both social impact and financial performance metrics that appeal to institutional and family office investors.
The Canadian Cancer Society joined as a foundational partner in the initiative, committing up to $10 million in capital. This partnership creates a unique structure combining venture capital investment expertise with the established scientific networks of two of Canada's largest cancer charities. The fund's investor base includes impact- and mission-driven foundations and family offices, notably Rally Assets (Realize Fund I), Boann Social Impact, and Northpine Foundation. All capital committed to date represents new funding directed toward Canada's life sciences innovation sector.
The fund has already approved its first investment in a Canadian company and is advancing a pipeline of cancer-focused opportunities. The stated dual objective is to translate Canadian scientific advances into transformative products for patients while generating strong economic returns for investors. This structure reflects a broader trend of integrating philanthropic missions with venture capital returns, positioning the fund to address both social impact and financial performance metrics that appeal to institutional and family office investors.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.